BPC-157 in Australia: TGA Rules and Legal Status

Australia became the first country to specifically schedule BPC-157 when the Therapeutic Goods Administration (TGA) classified it as Schedule 4 (Prescription Only Medicine) in June 2024. This makes Australia's approach to BPC-157 more explicit than the regulatory frameworks in the US, EU or UK. The BPC-157 Australia framework is the clearest of any country. Possession without a prescription is a regulatory breach.

Is BPC-157 Legal in Australia?

Schedule 4 Classification

Under the Poisons Standard (maintained at legislation.gov.au), BPC-157 is classified as Schedule 4, Prescription Only Medicine. This classification means the substance can only be supplied with a valid prescription from an AHPRA-registered medical practitioner. It cannot be sold over the counter, marketed as a supplement or purchased as a research chemical for personal use.

What Schedule 4 Means

Certain medications categorized as Schedule 4 must be prescribed because their effects require medical supervision for safe use. In addition, Schedule 4 medications include antibiotics, certain types of benzodiazepines, medications used to reduce blood pressure, and many other common prescription drugs. Being part of schedule 4 does not mean that a drug is controlled like a schedule 8 or 9 drug. BPC-157 falls under the same regulations as the normal prescription drugs.

How Australian Scheduling Works

The Poisons Standard

The Poisons Standard (which is also known as the Standard for the Uniform Scheduling of Medicines and Poisons, SUSMP) is maintained by the TGA. The Poisons Standard categorizes various substances into schedules according to their level of regulation. The different schedules range from Schedule 2 (Pharmacy Medicine, which can be sold without a prescription by a pharmacist) to Schedule 9 (Prohibited Substance, which may only be obtained through research). BPC-157 falls under Schedule 4, which means that it requires a prescription, however, it does not come with the restrictions imposed by Schedule 8 (Controlled Drug) and Schedule 9.

Why Australia Scheduled BPC-157

Ever since its inception, Australia has been one of the leading countries to act as the TGA follows a cautious approach with unapproved peptides. The scheduling decision shows the increased availability of BPC-157 in the online market, while also observing that no human clinical trials have been completed that would provide evidence of its efficacy and safety. The TGA's decision to classify it as one requiring a prescription reflects regulatory intention to control access to the substance through health care instead of letting it be sold in the unregulated research chemical market.

How to Access BPC-157 in Australia

Standard Prescription

An AHPRA-registered medical practitioner can prescribe BPC-157 for an individual patient. The prescription is filled through a compounding pharmacy that prepares the formulation. This is the most straightforward access pathway and mirrors how other Schedule 4 medicines are dispensed.

Special Access Scheme (SAS)

The Special Access Scheme of TGA is allowing the prescribers to procure medical items that may not be present on ARTG. Several SAS pathways exist but SAS Category B is one of the most used pathways for acquiring medicines that are unapproved. For SAS B, prescriber needs to apply for the permission of TGA to give the drug to specific patient. Application consists of details about clinical reasoning and informed consent.

Authorised Prescriber Framework

Another option available is the Authorised Prescriber (AP) pathway. Under the given method, a medical professional contacts the TGA for permission to prescribe a certain drug not cleared by the relevant authorities to a group of patients, not requiring individual approvals. Once it is approved, the authorised prescriber obtains the right to prescribe BPC-157 to eligible patients in accordance with the guidelines established. This method is considered to be more effective for the doctors involved in treating consecutive patients with one and the same substance.

Import Rules

Personal Importation

Australia has strict rules about importing prescription medicines. Under the personal importation scheme, individuals can import up to a 3-month supply of a prescription medication for personal use. However, the medication must be for a condition the person has been diagnosed with, and they should be able to provide evidence of a prescription if requested by customs. Importing BPC-157 without a prescription would not qualify under the personal importation scheme.

Customs Enforcement

The Australian Border Force (ABF) collaborates with the Therapeutic Goods Administration (TGA) in preventing the entry of unauthorized therapeutic products into Australia. The ABF can confiscate shipping containers carrying BPC-157 if they contain no proof of prescription to allow the import of the medicinal substance. As a result, there can be confiscation of the products, warnings, and penalties. Australia's enforcement activities regarding drug imports is generally considered to be more active compared to the US and the UK.

Comparison with Other Countries

Australia vs. United States

Australia's approach is more explicit than the US. The US has not specifically scheduled BPC-157; it falls through gaps in the regulatory framework as a not-approved, not-controlled, not-supplement substance. Australia created a clear legal category for it. Australian buyers have a defined legal pathway (prescription from an AHPRA-registered practitioner), while US buyers navigate a grey zone of research chemical vendors and telehealth clinics.

Australia vs. Europe

There is no EU member state that has made plans to schedule BPC-157 specifically. Buyers in Europe are confronted with a hodgepodge of national regulations and compliance regimes. In contrast, the Australian system is unified through a single federal classification. For further information, see our Europe page